Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly?

GÜLER ÖZTÜRK
KAZİME GONCA AKBULUT
ŞEVİN GÜNEY

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
ÖZTÜRK, GÜLER; AKBULUT, KAZİME GONCA; and GÜNEY, ŞEVİN (2020) "Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly?," Turkish Journal of Medical Sciences: Vol. 50: No. 6, Article 2. https://doi.org/10.3906/sag-2005-356
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss6/2

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly?

Güler ÖZTÜRK1*, Kazime Gonca AKBULUT1, Şevin GÜNEY2

1Department of Physiology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
2Department of Physiology, Faculty of Medicine, Gazi University, Ankara, Turkey

Abstract: The aim of this review is to summarize current studies on the relationship between melatonin and aging. Nowadays, age-related diseases come into prominence, and identifying age-related changes and developing proper therapeutic approaches are counted as some of the major issues regarding community health. Melatonin is the main hormone of the pineal gland. Melatonin is known to influence many biological processes in the body, including circadian rhythms, the immune system, and neuroendocrine and cardiovascular functions. Melatonin rhythms also reflect the biological process of aging. Aging is an extremely complex and multifactorial process. Melatonin levels decline considerably with aging and its decline is associated with several age-related diseases. Aging is closely associated with oxidative damage and mitochondrial dysfunction. Free radical reactions initiated by the mitochondria constitute the inherent aging process. Melatonin plays a pivotal role in preventing age-related oxidative stress. Coronavirus disease 2019 (COVID-19) fatality rates increase with chronic diseases and age, where melatonin levels decrease. For this reason, melatonin supplementation in elderly could be beneficial in COVID-19 treatment. Therefore, studies on the usage of melatonin in COVID-19 treatment are needed.

Key words: Aging, apoptosis, COVID-19, immune system, melatonin, oxidative stress

1. Introduction
During the aging process, the cell’s ability to cope with external and internal stress and its functional capacity is diminished by time. Increased morbidity and mortality rates for several diseases accompany this process. Since aging is an extremely complex and multifactorial process [1], it is impossible to describe it using a single mechanism. Many theories have been proposed to explain the process of aging. However, none of them appear to be entirely convincing. Modern biologic theories of aging in humans can be considered under two main categories: programmed and damage or error theories [2]. The programmed theory has three subcategories: programmed longevity, endocrine theory, and immunological theory. The damage or error theory has several subcategories such as wear and tear theory, rate of living theory, cross-linking theory, free radicals theory, and somatic DNA damage theory [2].

Melatonin [N-acetyl-5-methoxytryptamine] is associated with almost all aging theories and it is primarily released from the pineal gland with a circadian rhythm. Therefore, the pineal gland is prominent in aging theories. In addition retina, lachrymal glands, Harderian gland, gastrointestinal tract, thrombocytes, and bone marrow are other sources of melatonin release [3]. Thus, melatonin is considered to be a wide-spread physiological mediator [4]. Melatonin is also a potent free radical scavenger and affects the immune system [5,6].

2. Melatonin, aging, and oxidative stress
Melatonin synthesis decreases during the aging process; a decrease seen in both pineal and plasma levels of melatonin. In rodents, the rate of aging process and onset of age-related diseases can be delayed by exogenous melatonin treatment [5]. The lifespan enhancing effect of melatonin is linked with its antiproliferative feature. Melatonin affects both normal and tumoral proliferation of gastrointestinal cells [7,8].

In terms of the biology of aging, attenuated basal metabolic rate and physiologic performance in elderly mammals relies largely on mitochondria. Mitochondria are the main source of adenosine triphosphate (ATP) and also play a prominent role in several cellular processes, such as beta oxidation of fatty acids, synthesis of phospholipids, calcium signaling, production of reactive oxygen species (ROS), and apoptosis [9].

Free radical theory of aging explains the aging process based on the functional dysfunction of mitochondria.
As is already known, mitochondria are the main site for oxygen consumption, and ROS production; thus, they are also a main target for oxy-radical dependent cellular damage. Attenuated mitochondrial respiration affects lifespan by changing intracellular ROS balance [10,11]. There are some studies which have shown that electron transfer was reduced in mitochondria isolated from elderly animals [12]. Moreover, it has been shown that there is a positive correlation between reduced fluidity of cellular membranes, including mitochondrial membranes, and increased lipid peroxidation during aging [13]. An age-dependent decrease in the activity of manganese superoxide dismutase (Mn-SOD), and increase in the levels of thiobarbituric acid reactive products (TBARS), and carbonyl compounds have been found in brain tissue [14]. Higher oxidation levels indirectly change cellular redox potential, and decreases glutathione (GSH), ATP levels, and reduced NADH/NADPH balance. Due to these alterations, permeability of mitochondrial transition pores (MPTP) increases, and apoptosis is stimulated. It has been reported that protein carbonyl compounds, TBARS, hydroperoxide, and 8-hydroxydeoxyguanosine levels in brain mitochondria were increased with aging [15].

Due to its lipophilic and hydrophilic properties, melatonin can easily diffuse into all cellular and intracellular compartments, and can pass through the blood-brain barrier. Moreover, no specific binding site or receptor is required for its free radical scavenger effect [16,17]. The pyrrole ring structure of melatonin provides higher capacity to entrap $O_2^\cdot\,$ and $\cdot$OH radicals. It has been shown that melatonin is five times more effective than endogenous free radical scavenger glutathione, and fifteen times more effective than mannitol, which is an exogenous free radical scavenger. This evidence actually emphasizes that melatonin is a much more powerful antioxidant against $\cdot$OH radical, compared with the aforementioned antioxidants. The antioxidant effect of melatonin occurs by trapping the $O_2^\cdot\,$ radical via the indolyl cation radical, which is formed by the reaction of melatonin and the $\cdot$OH radical [5]. Melatonin is found intensively in subcellular compartments, such as the nucleus and mitochondria [18–20]. Mitochondria and mitochondrial dysfunction play a role in the cellular self-destruction processes, including apoptosis, autophagy, and necrosis [21]. The mitochondrial DNA (mtDNA) is more vulnerable than nuclear DNA as it is not enclosed within basic histones. The mtDNA damage in aging humans is 10-fold higher compared with nuclear DNA [21].

Although mitochondria are the main source of ROS formation, mitochondria are also the primary targets of ROS attacks [22].

Acuña-Castroviejo et al. reported that age-dependent mitochondrial oxidative stress was prevented by melatonin treatment [23]. Melatonin reduces free radical formation, and protects the cell membrane from free radical attacks. It also plays a pivotal role for mitochondrial homeostasis by optimizing the transfer of electrons through the electron transport chain in the inner mitochondrial membrane [6,19,24,25]. Rodríguez et al. reported that melatonin treatment restored mitochondrial ATP production in heart cells. They also showed that long term melatonin treatment prevents mitochondrial function deficiency and oxidative stress without any side effects caused by the melatonin [26].

It is already known that oxidative stress and the ischemia-reperfusion process take part in the pathogenesis of several diseases, like Alzheimer's disease, Parkinson's disease, and Diabetes mellitus [12]. Likewise there is a linear relationship between oxidative stress and aging; aging is a major risk factor for a variety of neurodegenerative diseases [27]. Increased free radical levels in tissues during aging processes have been reported by several studies [28–30].

Gastrointestinal tract derived melatonin is estimated to be approximately 400 times higher than the amount produced by the pineal gland [31]. Studies in mice and rats have shown that melatonin and its specific binding sites are found especially in the colon mucosa [32]. As a broad spectrum antioxidant, and with its free radical scavenging feature, melatonin ameliorates mucosal defense against various irritants and improves gastrointestinal system (GIS) lesions such as esophagitis, gastritis, peptic ulcer, and stomatitis [33]. Callagan et al. showed that hyperplasia developed in the small intestine and colon crypts after pinealectomy [7]. Melatonin has been shown to improve immune functions of the intestine, reduce peristalsis, and regulate fecal water content [31].

Melatonin is known to suppress tumor development. Deterioration of melatonin release has been closely associated with an increased incidence of colorectal cancer. In addition to colorectal cancer, melatonin is also related to the tumor onset, prognosis, and prevention of various cancers of the gastrointestinal tract, such as cholangiocarcinoma, hepatocarcinoma and pancreatic carcinoma. Melatonin exerts its antitumoral effect by decreasing cellular proliferation, autophagy, metastasis, and angiogenesis while activating apoptosis and colon cancer immunity [34].

As aforementioned, melatonin is a rather powerful and effective endogenous radical scavenger [35], and attenuates increased oxidative stress caused by several toxic substances like safrole and paraquat in tissues [36,37].

Besides this, exogenous administration of melatonin also has beneficial effects in terms of oxidative stress. Akbulut et al. previously showed that melatonin treatment prevents age-related oxidative stress, while it...
enriches antioxidant defense in the cerebral cortex and hippocampus [29]. Güney et al. showed that melatonin treatment attenuates H$_2$O$_2$ production and age-related increased lipid hydroperoxide formation in the liver and heart [30].

Nitric oxide (NO), synthesized by nitric oxide synthase (NOS), behaves as either a prooxidant or neuroprotective agent [38,39]. Since the breakdown of nitric oxide occurs in a very short time, its demission products nitrate and nitrite are used for measuring the nitric oxide levels [40]. NOx refers to nitric oxide and is obtained by subtracting nitrate from nitrite. Depending on its local concentration or existing cell type, NO can stimulate apoptosis, as well as maintaining cellular survival [41]. NOS activity has been shown in several brain areas, such as the cerebral cortex, cerebellum, hippocampus, and hypothalamus [42].

The aging process occurs along with inflammation, oxidative stress, and increased expression of inducible NOS (iNOS) in several tissues [43,44]. The relationship between aging and NO is still contradictory, and needs to be clarified [45]. Akbulut et al. showed that NOx levels in temporal cortex increased parallel with age. In the same study they also showed that short term melatonin treatment led to increased NO levels in the cortex; however, it was not effective for the hippocampus [46].

Organisms have powerful defense mechanisms against oxidative stress including antioxidant enzymes. Efficacy of antioxidant enzymes, however, diminishes with aging [28,47]. Glutathione is the most important nonprotein thiol compound which balances ROS in brain tissue. GSH redox cycle is essential for the scavenging of cellular free radicals. It maintains homeostasis via de novo glutathione synthesis and redox cycle. It has been reported that age-dependent increased oxidative stress diminished glutathione pools of brain mitochondria by half, and increased oxidized GSH levels [48]. Zhu et al. found that GSH levels were decreased; however, oxidized glutathione (GSSG) and GSSG/GSH levels were increased in several sites in the brain, such as the cortex, hippocampus, striatum, and cerebellum [49]. In several brain areas of rats at different ages, Sandhu et al. reported a decrease in the levels of SOD, GSH, glutathione reductase (GRd), and glutathione peroxidase (GPx) [50]. Even though mitochondrial antioxidant defense mechanisms depend on GSH, mitochondria itself cannot synthesize GSH [51–53]. GSH is taken into mitochondria from cytosol via a multicomponent transporter system [53,54]. Melatonin increases GPx, GRd, SOD, and catalase (CAT) gene expressions and enzyme activities in both pharmacological and physiological doses [55]. During the aging process, mitochondrial GPx levels increase in the brain, while melatonin treatment diminishes mitochondrial GPx levels in both young and elderly rats [56]. Melatonin treatment also enhances mitochondrial SOD levels in elderly rats, and prevents the reduction of SOD/GPx and GR/GPx ratios [56]. Indeed melatonin treatment has been found to increase renal SOD activity and GSH levels and decrease NOx levels in renal ischemia/reperfusion injury in rats [57].

3. Melatonin and apoptosis
Oxidative stress is known to stimulate apoptosis, and depending on the tissue type, apoptosis increases by age [58]. Apoptosis is a complicated process involving a cascade mechanism that employs many proteins [59]. The key enzymes in this process are the caspases. Caspases are a family of cysteine proteases widely known as the principal mediators of the apoptotic cell death response [59]. Exogenous melatonin administration has been shown to attenuate age-related increased caspase 3 activity in frontal and temporal cortices, and gastric mucosa of elderly rats [46,60]. Melatonin is known to be effective on antiapoptotic Bcl2 and apoptotic Bax proteins [61]. An excessive amount of ROS can be produced during aging, or formed by increased metabolic rate or environmental stress. In the presence of excessive ROS, melatonin stimulates ERK1/2 signaling pathway by receptor-dependent or -independent mechanisms, and increases expressions of antioxidants and detoxification genes, like glutathione and its enzymes via stimulation of transcription factors such as Nf-, AP-1, and Nrf2 [62]. As a result levels and activity of antioxidant enzymes such as GSH-Px, GSH-Rd, CAT, and GSH/GSSG ratio were enhanced as well as redox-sensitive Bcl2 or Bcl2/Bax ratio. Several studies reported that melatonin, decreased ROS production via controlling the mitochondrial damage and signaling functions of mitochondria, and augmented the activity of antiapoptotic Bcl2 [63–65].

P53 protein is an important transcription factor, related to the maintenance of genomic integrity by controlling the cell cycle progress and cellular survival [66]. It either ceases the progression of the cell cycle or stimulates apoptosis circumstantial with the conditions which cause genomic stress (DNA damage, hypoxia, etc.) [67]. DNA double strand breaks, base modifications, and point mutations may occur because of ROS attacks [68]. In the case of DNA damage, P53 gene expression is increased. Melatonin has different effects on apoptotic processes depending on the cell type. It increases p53 activity in tumor cells while protects other cells such as immune cells or neurons [59,69]. There are some studies about the antiproliferative effect of melatonin on tumor cells. For example Mediavilla et al. showed that melatonin displays an antiproliferative effect on MCF-7 human breast cancer cells by retaining cell cycle and increasing p53 activity [69]. Apoptotic cell death in LNCaP androgen sensitive prostate cancer cells depend on p53. Melatonin increases apoptosis and
stimulates p53 and p21 in these cells in a dose dependent manner [70]. However, in some other studies on the effect of melatonin on apoptosis in gastric mucosa during aging, the exogenous melatonin administration on p53 levels was not significant [60].

In an experimental diabetes model, an increase in apoptotic cell number is observed, and downregulation of Bcl-2, attenuation of activities of p53, and caspases 3, 8, and 9 have been reported. Melatonin administration throughout 21 days reduced apoptotic cell number and activities of p53, and caspases 3,8, and 9, while it enhanced Bcl2 levels [71]. Sinanoglu et al. also showed that melatonin pretreatment against renal inflammation in rats prevented caspase3-dependent cell apoptosis. The antioxidant effect of melatonin may partly depend on its antiapoptotic effect [72]

4. Melatonin and inflammation
The anti-inflammatory feature of melatonin is explained with several molecular mechanisms, and is related to the modulation of several transcription factors like NFκB, hypoxia inducible factor, nuclear factor erythroid 2-related factor 2, and with modulation of iNOS expression. NO is the key molecule for the inflammation. Its reaction with superoxide leads to peroxynitrite formation, which triggers nitration of tyrosine residues in cellular proteins, and hence increases cytotoxicity [73]. As it is shown in several studies, melatonin inhibits the expressions of iNOS and cyclooxygenase. It also reduces the levels of several mediators like leukotriens, cytokines, chemokins, adhesion molecules and reduces production of excessive amount of NO [74–78]. NOS subtypes have different effects in neuropathologic conditions, nNOS and iNOS act together in neurogenerative processes, while eNOS diminishes neuronal injury. Melatonin reduces levels of iNOS and eNOS; however, it increases eNOS levels in a variety of clinical manifestations such as brain ischemia, spinal cord injury, and diabetic neuropathy [79–82]

5. Melatonin and the immune system
Both cellular and humoral immune responses decrease with age. As a result of decreased immune system activity people can face increased risk factors, such as cancer, infections, and autoimmune diseases. Due to its anti-inflammatory feature and effects on the immune system, melatonin is one of the most prominent candidates used to explain aging physiopathology [28,83]. Melatonin has been shown to restore age-related decline in immune responses [84]. Notably, the main target of melatonin is the thymus which is the central organ of the immune system [85]. The effects of melatonin on thymus endocrine activity and immune functions are partly dependent on its relation to zinc, which is an essential component of more than 200 enzymes [84,86,87]. Zinc contributes to the age related changes in the immune system, and the zinc pool is altered with aging. Melatonin is reported to regulate zinc turnover. Öztürk et al. showed that liver zinc levels were reduced by age and melatonin recovered age-related decrement in zinc levels of the thymus tissue in elderly rats [87]. Moreover, in another study, melatonin treatment has been shown to increase zinc level in the small intestines of young rats during night time, while it increased zinc levels in salivary glands during day and night time via the zinc absorption from small intestines [88].

With age, functional activity of natural killer (NK) cells, lymphokine secretion, in particular IL-2 synthesis and IL-2 receptor expression, diminish together with T cell response [89,90]. Aging decreases humoral immunity; however, decrement in cellular immunity is more specific. Melatonin treatment enhances Ig and IL-2 responses. Akbulut et al. reported that melatonin administration to elderly rats increased IgG and IgM levels significantly [91]. Inhibition of melatonin synthesis in mice, attenuates primary antibody response, and decreases cell numbers in the spleen and thymus [85].

6. Melatonin and coronavirus disease 2019
In December 2019, the third pathogenic human coronavirus (HCoV) was identified as the cause of coronavirus disease 2019 in Wuhan, China. Coronaviruses (CoVs) are RNA viruses infecting both human and animals. They typically affect the respiratory tract of mammals, including humans, and lead to mild to severe respiratory tract infections [92]. The world is in the grip of the coronavirus disease 2019 (COVID-19) pandemic and COVID-19 continues to spread to all countries. No specific treatment has yet been found for COVID-19. Vaccination and drug studies are in progress.

Viral infections are often associated with immune-inflammatory injury, in which the level of oxidative stress increases significantly and has negative effects on the function of multiple organs [92]. Melatonin plays a key role in several biological processes, and offers an alternative point of view in the management of viral infections. Even though melatonin cannot eradicate or even curb the viral replication or transcription, due to its anti-inflammatory and antioxidant effects, melatonin has been suggested as a candidate drug to relieve patients’ clinical symptoms in antiviral treatment [92,93]. In addition, it has been suggested that melatonin treatment may prolong patients’ survival time, which may provide a chance for recovery of the immune system and eventually eradication of the virus. Melatonin indirectly targets several HCoV cellular targets, including ACE2, BCL2L1, JUN, and IKBKB [92]. Therefore, its usage in COVID-19 treatment might be beneficial. COVID-19 fatality rates increase with chronic diseases and age, where melatonin levels are low.
Melatonin supplementation can reduce the risk of influenza and COVID-19 incidence. Several studies have proved the positive effects of melatonin in attenuating acute respiratory stress induced by virus, bacteria, and radiation [93]. It has been suggested that melatonin may have supportive adjuvant utility in treating COVID-19 induced pneumonia, acute lung injury (ALI), and acute respiratory distress syndrome (ARDS). In fact melatonin has been found to reduce the proinflammatory cytokines that trigger inflammation and pneumonia in lungs [93].

A cytokine storm also prevails in patients with COVID-19. When compared to that of SARS patients, interleukin 1β (IL-1β), interferon γ (IFNγ), interferon-inducible (IP-10), and monocyte chemoattractant protein 1 (MCP1), IL-4 and IL-10 levels increased significantly in the blood of patients with COVID-19. A potential repressed immune function is seen in COVID-19 patients with the hypoalbuminemia, lymphopenia, and neutropenia, and also there is a decreased percentage of CD8+ T cell. A T-helper-2 (Th2) product IL-10 is an antiviral and coronaviruses lead to a significant decrease in this agent. As a result, inflammation is a major feature in COVID-19 patients. Activated cytokine storm, depressed immune system, and excessive inflammation may contribute to the pathogenesis of COVID-19. Thus, overproduction of these cytokines and chemokines contributes to the prognosis of the disease [93].

Experimental SARS-CoV models support this cytokine storm hypothesis related to coronaviruses. One of those experimental models revealed that the severity of ALI was accompanied by an elevated expression of inflammation-related genes rather than increased viral titers. Therefore, Zhang et al. suggested that attenuation of the cytokine storm may provide better results in treatment [93].

Because of its anti-inflammatory, antioxidative, and immune enhancing features, melatonin may have indirect antiviral actions. [94]. The decrease in pineal and mitochondrial melatonin contributes to an increase in the replication and severity of many viral infections [95]. Indeed, melatonin treatment has been shown to alleviate the symptoms of infection and decrease virus load in mice infected with encephalitis viruses.

SARS-CoV2 is believed to cause severe lung pathology by triggering pyroptosis, a highly inflammatory form of programmed cell death. [96]. Pyroptosis in immune system cells can lead to symptoms like lymphopenia that blocks an effective immune response to the virus. It has been proposed that programmed cell death caused by coronaviruses can be inhibited by melatonin. Thus, melatonin intake can improve the protective mechanisms of the body against infections. [96].

Ventilation has been reported to increase pulmonary inflammation in acute lung injury and increased oxidative stress in alveoli. As mentioned above, because of the highly effective role of melatonin against oxidative stress, it is reported that melatonin can help to resolve the contradiction between the urgent clinical necessity to deliver mechanical ventilation to a patient and the threat that ventilation may have [96]. As a result, the antiinflammation, antioxidation, and immune enhancing effects of melatonin might be useful in reducing the risk of COVID-19.

Moreover, melatonin has been shown to be a vasodilator in the pulmonary arteries, and this effect of melatonin has been reported to be very fast [96]. Due to its vasodilating effect on pulmonary vascular vessels, the role of melatonin in the treatment of COVID-19 should be investigated and supported by scientific data [97].

7. Conclusion
The pineal gland is considered to be the body's "biological clock", and melatonin is the chief secretory product of this gland. Melatonin plays an important role in many processes in the body, especially in healthy aging and prevention of free-radical-related diseases. Melatonin, as an endogenous synchronizer, affects the regulation of the other hormonal rhythms. The decrease in melatonin production and altered melatonin rhythms with aging can lead to an inhibited immune system. These changes can cause an increase in risk of disease in elderly. Melatonin could reduce the risk of COVID-19 in the elderly with a weak immune system. The use of melatonin as an antiviral immunostimulant should be supported by studies.

References
1. Espino J, Pariente JA, Rodriguez AB. Oxidative Stress and immunosenescence: therapeutic effects of melatonin. Oxidative Medicine and Cellular Longevity 2012; Article ID 670294. doi: 10.1155/2012/670294
2. Jin K. Modern biological theories of aging. Aging and Disease 2010; 1 (2): 72-74.
3. Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cellular and Molecular Life Sciences 2008; 65: 2001-2018. doi: 10.1007/s00018-008-8001-x
4. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Reviews 1991; 12 (2): 151-180. doi: 10.1210/edrv-12-2-151
5. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. Journal of Pineal Research 1993; 14 (4): 151-168. doi: 10.1111/j.1600-079X.1993.tb00498.x
6. Acuña-Castroviejo D, Escames G, Rodriguez MI, Lopez, LC. Melatonin role in the mitochondrial function. Frontiers in Bioscience 2007; 12: 947-963.
7. Callaghan BD. The effect of pinealectomy on the crypts of functioned rat colon. Journal of Pineal Research 1997; 23: 117-122. doi: 10.1111/j.1600-079X.1997.tb00343.x

8. Cos S, Mediavilla MD, Fernández R, González-Lamuño D, Sánchez-Barceló EJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? Pineal Research 2002; 32 (2): 90-96.

9. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309 (5733): 481-484. doi: 10.1126/science.1112125

10. Navarro A, Boveris A. Rat brain and liver mitochondria develop oxidative stress and lose enzymatic activities on aging. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 2004; 287 (5): R1244-R 1249. doi: 10.1152/ajpregu.00226.2004

11. Vázquez-Memije ME, Capin R, Tolosa A, El-Hafidi M. Analysis of age-associated changes in mitochondrial free radical generation by rat testis. Molecular and Cellular Biochemistry volume 2008; 307: 23-30. doi: 10.1007/s11010-007-9580-9

12. Beckman KB, Ames BN. Endogenous oxidative damage of mtDNA. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999; 424 (1-2): 51-58. doi: 10.1016/S0027-5107(99)00007-X

13. Laganiere S, Yu BP. Modulation of membrane phospholipid fatty acid composition by age and food restriction. Gerontology 1993; 39 (1): 7-18. doi: 10.1159/000213509

14. Boveris A, Navarro A. Brain mitochondrial dysfunction in aging. IUBMB Life 2008; 60 (5): 308-314. doi: 10.1002/iub.46

15. Sastre J, Pallardo FV. Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000; 49 (5): 427-435. doi: 10.1080/15216540010281

16. Reiter RJ. Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals European Journal of Endocrinology 1996; 134 (4): 412-420. doi: 10.1530/eje.0.1340412

17. Hardeland R, Reiter RJ. The significance of the metabolism of the neurohormone melatonin. Neuroscience & Biobehavioral Reviews 1993; 17 (3): 347-356. doi: 10.1016/S0149-7634(05)80016-8

18. López A, García JA, Escames G, Venegas C, Ortiz F et al. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. Journal of Pineal Research 2009; 46 (2): 188-198. doi: 10.1111/j.1600-079X.2008.00647.x

19. Escames G, López A, García JA, García L, Acuña-Castroviejo D et al. The role of mitochondria in brain aging and the effects of melatonin. Current Neuropharmacology 2010; 8 (3): 182-193. doi: 10.2174/157051910792246245

20. Venegas C, García JA, Escames G, Ortiz F, López A et al. Extraneural melatonin: analysis of its subcellular distribution and daily fluctuations. Journal of Pineal Research 2012; 52 (2): 217-227. doi: 10.1111/j.1600-079X.2011.00931.x

21. Bondy SC, Sharman EH. Melatonin and the aging brain. Neurochemistry International 2007; 50(4): 571-580. doi: 10.1016/j.neuint.2006.12.014

22. Acuña-Castroviejo CD, Lopez LC, Escames G, Lopez A, Garcia JA et al. Melatonin-mitochondria interplay in health and disease. Current Topics in Medicinal Chemistry 2011; 11 (2): 221-240. doi: 10.2174/156802611794863517

23. Acuña-Castroviejo D, Carretero M, Doerrier C, López LC, García-Corzo L et al. Melatonin protects lung mitochondria from aging. Age (Dordr) 2012; 34 (3): 681-692. doi: 10.1007/s11357-011-9267-8

24. Martín M, Macías M, León J, Escames G, Khaldy H et al. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. The International Journal of Biochemistry & Cell Biology 2002; 34 (4): 348-357. doi: 10.1016/S1357-2725(01)00138-8

25. García JJ, López-Pingarrón L, Almeida-Souza P, Tres A, Escudero P et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. Journal of Pineal Research 2014; 56 (3): 225-237. doi: 10.1111/jpi.12128

26. Rodríguez MJ, Carretero M, Escames G, López LC, Maldonado MD et al. Chronic melatonin treatment prevents age-dependent cardiac mitochondrial dysfunction in senescence accelerated mice. Free Radical Research 2007; 41 (1): 15-24. doi: 10.1080/1071576060936359

27. Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiology of Aging 2002; 23 (5): 795-807. doi: 10.1016/S0197-4580(02)00019-2

28. Gonca Akbulut K, Gönlü B, Akbulut H. Differential effects of pharmacological doses of melatonin on malondialdehyde and glutathione levels in young and old rats. Gerontology 1999; 45 (2): 67-71. doi: 10.1159/000022065

29. Akbulut KG, Gönlü B, Akbulut H. Exogenous melatonin decreases age-induced lipid peroxidation in the brain. Brain Research 2008; 1238: 31-35. doi: 10.1016/j.brainres.2008.08.014

30. Güney S, Cumaoglu A, Öztürk G, Akbulut KG, Karasu C. Comparison of melatonin effect on oxidant status and antioxidant capacity in liver and heart of young and aged rats. International Journal of Gerontology 2013; 7 (1): 45-49. doi: 10.1016/j.ijge.2012.11.010

31. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Digestive Diseases and Sciences 2002; 47: 2336-2348. doi: 10.1023/A:1014307915919

32. Bubenik GA. Localization of melatonin in the digestive tract of the rat. Hormone Research in Paediatrics 1980; 12: 313-323. doi: 10.1159/000179137

33. Iravani S, Eslami P, Dooghae Moghadam A, Moazami B et al. The role of melatonin in colorectal cancer. Journal of Gastrointestinal Cancer 2019. doi: 10.1007/s12029-019-00336-4
34. Wu H, Liu J, Yin Y, Zhang D, Xia P et al. Therapeutic opportunities in colorectal cancer: focus on melatonin antioncogenic action. BioMed Research International 2019. 
doi: 10.1155/2019/9740568

35. Reiter RJ, Tan DX, Poeggener B, Menendez-Pelaye A, Chen LD et al. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Annals of the New York Academy of Sciences 1994; 719: 1-12. 
doi: 10.1111/j.1749-6632.1994.tb56817.x

36. Melchiorri D, Reiter RJ, Atta AM, Hara M, Burgos A et al. Potent protective effect of melatonin on in vivo paraglutamate-induced oxidative damage in rats. Life Sciences 1995; 56 (2): 83-89. 
doi: 10.1016/0024-3205(94)00417-q

37. Reiter RJ. Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Frontiers in Neuroendocrinology 1995; 16 (4): 383-415. 
doi: 10.1006/frne.1995.1014

38. Navarro A, Boveris A. Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria-targeted antioxidants. Advanced Drug Delivery Reviews 2008; 60 (13-14): 1534-1544. 
doi: 10.1016/j.addr.2008.05.002

39. Liu P, Jing Y, Zhang H. Age-related changes in arginine and its metabolites in memory-associated brain structures. Neuroscience 2009; 164 (2): 611-628. 
doi: 10.1016/j.neuroscience.2009.08.029

40. Ma L, Hu L, Feng X, Wang S. Nitrate and nitrite in health and disease. Aging and Disease 2018; 9 (5): 938-945. 
doi: 10.14336/AD.2017.1207

41. Kim PK, Kwon YG, Chung HT, Kim YM. Regulation of caspases by nitric oxide. Annals of the New York Academy of Sciences 2002; 962: 42-52. 
doi: 10.1111/j.1749-6632.2002.tb04054.x

42. McCann SM. The nitric oxide hypothesis of brain aging. Experimental Gerontology 1997; 32 (4-5): 431-440. 
doi: 10.1016/S0531-5565(96)00154-4

43. Li QX, Xiong ZY, Hu BP, Tian ZJ, Zhang HF et al. Aging-associated insulin resistance predisposes to hypertension and its reversal by exercise: the role of vascular vasorelaxation to insulin. Basic Research in Cardiology 2009; 104 (3): 269-284. 
doi: 10.1007/s00395-008-0754-8

44. Song W, Kwak HB, Kim JH, Lawler JM. Exercise training modulates the nitric oxide synthase profile in skeletal muscle from old rats. Journal of Gerontology: Biological Sciences 2009; 64 (5): 540-549. 
doi: 10.1093/gerona/glp021

45. Blanco S, Molina FJ, Castro L, Del Moral ML, Hernandez R et al. Study of the nitric oxide system in the rat cerebellum during aging. BMC Neuroscience 2010; 11: 78. 
doi: 10.1186/1471-2202-11-78

46. Akbulut KG, Guney S, Cetin F, Akgun HN, Aktas SH et al. Melatonin delays brain aging by decreasing the nitric oxide level. Neurophisiology 2013; 45: 187-192. 
doi: 10.1007/s11062-013-9368-3

47. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. Mechanisms of Ageing and Development 2004; 125 (10-11): 811-826. 
doi: 10.1016/j.mad.2004.07.009

48. Cocco T, Sgobbo P, Clemente M, Lopriore B, Grattaglino I et al. Tissue-specific changes of mitochondrial functions in aged rats: Effect of a long-term dietary treatment with N-acetylcysteine. Free Radical Biology and Medicine 2005; 38 (6): 796-805. 
doi: 10.1016/j.freeradbiomed.2004.11.034

49. Zhu Y, Carvey PM, Ling Z. Age-related changes in glutathione and glutathione related enzymes in rat brain. Brain Research 2006; 1090 (1): 35-44. 
doi: 10.1016/j.brainres.2006.03.063

50. Sandhu SK, Kaur G. Alterations in oxidative stress scavenger system in aging rat brain and lymphocytes. Biogerontology 2002; 3 (3): 161-173. 
doi: 10.1023/A:1015643107449

51. Phung CD, Ezieme JA, Turrens JF. Hydrogen peroxide metabolism in skeletal muscle mitochondria. Archives of Biochemistry and Biophysics 1994; 315 (2): 479-482. 
doi: 10.1016/abbi.1994.1528

52. Bai J, Rodriguez AM, Melendez JA, Cederbaum AI. Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury. The Journal of Biological Chemistry 1999; 274 (37): 26217-26224. 
doi: 10.1074/jbc.274.37.26217

53. Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX et al. Melatonin and mitochondrial function. Life Sciences 2004; 75 (7): 765-790. 
doi: 10.1016/j.lfs.2004.03.003

54. McKernan TB, Woods EB, Lash LH. Uptake of glutathione and glutathione-related enzymes in rat brain. Biogerontology 2002; 3 (3): 161-173. 
doi: 10.1016/j.lfs.2004.03.003

55. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F et al. Regulation of antioxidant enzymes: a significant role for melatonin. Journal of Pineal Research 2004; 36 (1): 1-9. 
doi: 10.1046/j.1600-079x.2003.00092.x

56. Öztürk G, Akbulut KG, Güney Ş, Acuña-Castroviejo D. Age-related changes in the rat brain mitochondrial antioxidative enzyme ratios: modulation by melatonin. Experimental Gerontology 2008; 43 (9): 706-711. 
doi: 10.1016/j.exger.2012.06.011

57. Sezgin G, Öztürk G, Güney S, Sinanoğlu O, Tunçdemir M. Protective effect of melatonin and 1,25-dihydroxyvitamin D3 on renal ischemia-reperfusion injury in rats. Renal Failure 2013; 35 (3): 374-379. 
doi: 10.3109/0886022X.2012.760409

58. Behrens MI, Silva M, Schmied A, Salech F, Manzur H et al. Age-dependent increases in apoptosis/necrosis ratios in human lymphocytes exposed to oxidative stress. The Journals of Gerontology: Series A 2011; 66 (7): 732-740. 
doi: 10.1093/gerona/grl039

59. Tsapras P, Nezis IP. Caspase involvement in autophagy. Cell Death Differentiation. 2017; 24 (8): 1369-1379. 
doi: 10.1038/cdd.2017.43
60. Akbulut KG, Akbulut H, Akgun N, Gönul B. Melatonin decreases apoptosis in gastric mucosa during aging. Aging Clinical and Experimental Research 2012; 24 (1): 15-20. doi: 10.3275/7568

61. Caballero B, Vega-Naredo I, Sierra V, Huidobro-Fernández C, Soria-Valles C et al. Melatonin alters cell death processes in response to age-related oxidative stress in the brain of senescence-accelerated mice. Journal of Pineal Research 2009; 46 (1): 106-114. doi: 10.1111/j.1600-079X.2008.00637.x

62. Luchetti F, Canonico B, Betti M, Arcangletti M, Pilolli F et al. Melatonin signaling and cell protection function. The FASEB Journal 2010; 24: 3603-3624. doi: 10.1096/fj.10-154450

63. Yoo YM, Yim SV, Kim SS, Jang HY, Lea HZ et al. Melatonin suppresses NO-induced apoptosis via induction of Bcl-2 expression in PGT-immortalized pineal cells. Journal of Pineal Research 2002; 33 (3): 146-150. doi: 10.1034/j.1600-079X.2002.02899.x

64. Yalcin A, Kanit L, Sozmen EY. Altered gene expressions in rat hippocampus after kainate injection with or without melatonin pre-treatment. Neuroscience Letters 2004; 359 (1-2): 65-68. doi: 10.1016/j.neulet.2004.02.013

65. Fu J, Zhao SD, Liu HJ, Yuan QH, Liu SM et al. Melatonin promotes proliferation and differentiation of neural stem cells subjected to hypoxia in vitro. Journal of Pineal Research 2011; 51 (1): 104-112. doi: 10.1111/j.1600-079X.2011.00867.x

66. Somasundaram K. Tumor suppressor p53: regulation and function. Frontiers in Bioscience 2000; 5: D424-437.

67. Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. European Journal of Biochemistry 2001; 268 (10): 2784-2791. doi: 10.1046/j.1432-1327.2001.02228.x

68. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120 (4): 513-522. doi: 10.1016/j.cell.2005.02.003

69. Moccagatta MD, Cos S, Sánchez-Barceló EJ. Melatonin increases p53 and p21WA1 expression in MCF-7 human breast cancer cells in vitro. Life Sciences 1999; 65 (4): 415-420. doi: 10.1016/S0024-3205(99)00262-3

70. Kim CH, Yoo YM. Melatonin induces apoptotic cell death via p53 in LNCaP cells. The Korean Journal of Physiology and Pharmacology 2010; 14 (6): 365-369. doi: 10.4196/kjpp.2010.14.6.365

71. Amin AH, El-Missiry MA, Othman AI. Melatonin ameliorates metabolic risk factors, modulates apoptotic proteins, and protects the rat heart against diabetes-induced apoptosis. European Journal of Pharmacology 2015; 747:166-173. doi: 10.1016/j.ejphar.2014.12.002

72. Sinanoglu O, Sezgin G, Öztürk G, Tuncdemir M, Guney S et al. Melatonin with 1,25-dihydroxyvitamin D3 protects against apoptotic ischemia-reperfusion injury in the rat kidney. Renal Failure 2012; 34: 1021-1026. doi: 10.3109/0886022X.2012.708887

73. García-Medivilla MV, Sánchez-Campos S, González-Pérez P, Gómez-Gonzalo M, Majano PL et al. Differential contribution of hepatitis C virus NS5A and core proteins to the induction of oxidative and nitrosative stress in human hepatocyte-derived cells. Journal of Hepatology 2005; 43 (4): 606-613. doi: 10.1016/j.jhep.2005.04.019

74. Li JH, Yu JP, Yu HG, Xu XM, Yu LL et al. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators of Inflammation 2005; 2005 (4): 185–193. doi: 10.1155/MI.2005.185

75. Kireev RA, Tresguerres AC, García C, Ariznavarreta C, Vara E et al. Melatonin is able to prevent the liver of old castrated female rats from oxidative and pro-inflammatory damage. Journal of Pineal Research 2008; 45 (4): 394-402. doi: 10.1111/j.1600-079X.2008.00606.x

76. Mnrka L, Hock M, Rybová M, Pácha J. Melatonin inhibits prostaglandin E2- and sodium nitroprusside-induced ion secretion in rat distal colon. European Journal of Pharmacology 2008; 581 (1-2): 164-170. doi: 10.1016/j.ejphar.2007.11.031

77. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Alvarez-García V et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. British Journal of Cancer 2009; 101 (9): 1613-1619. doi: 10.1038/sj.bjc.6605336

78. Cuesta S, Kireev R, García C, Forman K, Escames G et al. Beneficial effect of melatonin treatment on inflammation, apoptosis and oxidative stress on pancreas of a senescence accelerated mice model. Mechanisms of Ageing and Development 2011; 132 811-12: 573-582. doi: 10.1016/j.mad.2011.10.005

79. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke 28 (6): 1283-1288. doi: 10.1161/01.STR.28.6.1283

80. Koh PO. Melatonin regulates nitric oxide synthase expression in ischemic brain injury. Journal of Veterinary Medical Science 2008; 70 (7): 747-750. doi: 10.1292/jvms.70.747

81. Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappab and Nrf2 cascades. Journal of Pineal Research 2011; 50 (2): 124-131. doi: 10.1111/j.1600-079X.2010.00821.x

82. Park S, Lee SK, Park K, Lee Y, Hong Y et al. Beneficial effects of endogenous and exogenous melatonin on neural reconstruction and functional recovery in an animal model of spinal cord injury. Journal of Pineal Research 2012; 52 (1): 107-119. doi: 10.1111/j.1600-079X.2011.00925.x

83. Cardinali DP, Esquifino AI, Srinivasan V, Pandi-Perumal SR. Melatonin and the immune system in aging. Neuroimmunomodulation 15 (4-6): 272-278. doi: 10.1159/000156470

84. Mocchegiani E, Bulian D, Santarelli L, Tibiladi A, Muzzioli M et al. The immuno-reconstituting effect of melatonin or pineal grafting and its relation to zinc pool in aging mice. Journal of Pineal Research 1999; 26 (4): 185-193. doi: 10.1034/j.1600-079X.1999.00029-9

85. Maestroni GJ. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993; 14 (1): 1-10. doi: 10.1111/j.1600-079X.1993.tb00478.x

86. Öztürk G, Çoşkun S, Erbaş D, Altunkaynak B. Effect of melatonin treatment on serum and tissue zinc levels in rats. The Journal of Trace Elements in Experimental Medicine 2002; 15 (1): 1-8. doi: 10.1002/jtra.1053
ÖZTÜRK et al. / Turk J Med Sci

87. Öztürk G, Akbulut KG, Afrasyap L, Sevinç D. Effect of melatonin treatment on liver and thymus Zinc Levels in Young and Middle-Aged Rats. The Journal of Trace Elements in Experimental Medicine 2004; 17 (1): 75–80. doi: 10.1002/jtra.10055

88. Özturk G, Akbulut KG, Afrasyap L. Age-related changes in tissue and plasma zinc levels: modulation by exogenously administered melatonin. Experimental Aging Research 2008 34 (4): 453-62. Erratum in: Experimental Aging Research 2009 35 (1): 152. doi: 10.1080/03610730802271922

89. Weigle W. The effect of aging on cytokine release and associated immunologic functions. Immunology and Allergy Clinics of North America 1993; 13: 551-569.

90. Srinivasan V, Maestroni GJ, Cardinali DP, Esquifino AI, Perumal SR et al. Melatonin, immune function and aging. Immunity and Ageing 2005; 2(17). doi: 10.1186/1742-4933-2-17

91. Akbulut KG, Gönül B, Akbulut H. The effects of melatonin on humoral immune responses of young and aged rats. Immunological Investigations 2001; 30 (1): 17-20. doi: 10.1081/IMM-100103687

92. Zhou Y, Hou Y, Shen J, Huang Y, Martin W et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery 2020; 6:14. doi: 10.1038/s41421-020-0153-3

93. Zhang R, Wang X, Ni L, Di X, Ma B et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sciences 2020; 250: 117583. doi: 10.1016/j.lfs.2020.117583

94. Reiter RJ, Ma Q, Sharma R. Treatment of Ebola and other infectious diseases: melatonin "goes viral". Melatonin Research 2020; 3 (1): 43-57. doi: 10.32794/mr11250047

95. Anderson G, Reiter RJ. Melatonin: Roles in influenza, COVID-19, and other viral infections. Reviews in Medical Virology 2020; 21:e2109. doi:10.1002/rmv.2109

96. Shneider A, Kudriavtsev A, Vakhrusheva A. Can melatonin reduce the severity of COVID-19 pandemic? International Reviews Immunology. 2020; 29:1-10. doi: 10.1080/08830185.2020.1756284

97. Herrera EA, González-Candia A. Comment on Melatonin as a potential adjuvant treatment for COVID-19. Life Sciences. 2020; 253:117739. doi: 10.1016/j.lfs.2020.117739